Wednesday, November 22, 2023 9:52:58 AM
09 Nov, 2023, 09:00 ET
https://www.prnewswire.com/news-releases/neurosense-therapeutics-to-present-at-upcoming-us-and-european-als-conferences-301983397.html
- Last patient completed the double-blind segment of PARADIGM, a Phase 2b ALS Trial
- Clinical efficacy top-line results from PARADIGM expected in December 2023
CAMBRIDGE, Mass., Nov. 9, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced scientific presentations at three upcoming conferences.
Neuroscience 2023
Mr. Nitai Kerem, NeuroSense's Scientific Project Manager, will present a poster on NeuroSense's latest biomarker data at Neuroscience 2023, the Society of Neuroscience's annual conference. This is the largest U.S. Neuroscience conference, bringing together scientists and physicians devoted to understanding the brain and the nervous system. The conference will be held in Washington D.C. on November 11th-15th, 2023.
ALS ONE's 6th Annual ALS Research Symposium
Dr. Shiran Zimri, VP of R&D at NeuroSense, will present the Company's latest clinical updates and findings in her talk titled "Shifting the Paradigm - A Biomarker Driven Approach for Studying Amyotrophic Lateral Sclerosis (ALS) Therapy Activity" at ALS ONE's 6th Annual ALS Research Symposium, to be held virtually on November 16th-17th, and 20th 2023. In addition to NeuroSense being a sponsor of this year's conference, this marks the fourth year NeuroSense will present at ALS ONE's symposium.
With a focus on the Company's Phase 2b PARADIGM PrimeC study, Dr. Zimri will present key elements of PrimeC's development program. The last patient has completed the double-blind segment of PARADIGM, with clinical efficacy results (secondary endpoints) expected in December 2023.
The 34th International Symposium on ALS/MND
Dr. Shiran Zimri and Dr. Ferenc Tracik, NeuroSense's Chief Medical Officer, will present a poster at the 34th International Symposium on ALS/MND, which brings together leading ALS and motor neuron disease (MND) experts, European patient advocacy groups, and ALS foundations, on December 6th-9th, 2023 in Basel, Switzerland.
"We believe NeuroSense's highly innovative approach of using biomarkers as a primary efficacy endpoint in our Phase 2b PARADIGM study will further elucidate the biological activity of PrimeC and help us to better understand the effect on people living with ALS," said Dr. Zimri. "We are excited to soon begin sharing the initial results of the double-blind segment of our Phase 2b trial to determine our drug's impact on efficacy."
About PARADIGM
NeuroSense's Phase 2b PARADIGM trial evaluating PrimeC's efficacy, as well as safety and tolerability, in people living with ALS. The study is randomized 69 people living with ALS in a 2:1 ratio to receive PrimeC or placebo, respectively. Primary endpoints of the study include assessment of ALS biomarkers, evaluation of clinical efficacy, improvement in quality of life, as well as safety and tolerability.
Recent NRSN News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/01/2024 01:24:12 PM
- NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial • PR Newswire (US) • 08/01/2024 01:15:00 PM
- NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression • PR Newswire (US) • 07/09/2024 01:27:00 PM
- NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug • PR Newswire (US) • 07/01/2024 12:00:00 PM
- NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results • PR Newswire (US) • 06/24/2024 01:00:00 PM
- NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal • PR Newswire (US) • 06/21/2024 08:30:00 PM
- NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit • PR Newswire (US) • 05/20/2024 01:00:00 PM
- NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning • PR Newswire (US) • 05/14/2024 01:05:00 PM
- NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients • PR Newswire (US) • 05/07/2024 12:45:00 PM
- NeuroSense Announces First Quarter 2024 Business Update • PR Newswire (US) • 05/02/2024 01:19:00 PM
- NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease • PR Newswire (US) • 04/22/2024 12:30:00 PM
- NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting • PR Newswire (US) • 04/18/2024 12:30:00 PM
- NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024 • PR Newswire (US) • 04/12/2024 12:30:00 PM
- NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement • PR Newswire (US) • 04/10/2024 11:16:00 PM
- NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics • PR Newswire (US) • 04/09/2024 12:30:00 PM
- NeuroSense Announces Year End 2023 Financial Results and Provides Business Update • PR Newswire (US) • 04/05/2024 01:29:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/22/2024 01:25:59 PM
- NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial • PR Newswire (US) • 02/21/2024 01:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 06:20:37 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 03:14:40 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/07/2024 02:38:16 PM
- NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule • PR Newswire (US) • 02/07/2024 02:27:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/09/2024 01:49:26 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/09/2024 01:48:26 PM
Kona Gold Beverages, Inc. Announces Strategic Initiatives and Corporate Direction Changes • KGKG • Aug 2, 2024 2:00 PM
POET and Luxshare Tech Expand Product Offerings for Artificial Intelligence Networks • POET • Aug 1, 2024 9:28 AM
Management Discusses Financial Filings of Global Arena Holding Inc., for 10-K 2023 and 10-Q, 1st Quarter 2024 • GAHC • Aug 1, 2024 9:14 AM
VAYK Announces LOI to Acquire $1 Million Home Service Company to Support Airbnb Business • VAYK • Aug 1, 2024 9:00 AM
Duane Forrester Joins INDEXR as SVP of Search • MONI • Jul 31, 2024 11:46 AM
Lingerie Fighting Championships Help Fulfill Death-Bed Promise With First Major Motion Picture • BOTY • Jul 31, 2024 9:00 AM